摘要
目的 观察α-2b干扰素联合顺铂膀胱粘膜下注射及术后膀胱灌注对预防膀胱移行细胞癌复发的远期临床疗效。方法 106例诊断为膀胱移行细胞癌的病人,随机分为两组。A组56例,采用术前60-90 min行膀胱内灌注顺铂50mg,术中用α-2b干扰素300万U加顺铂30mg,生理盐水稀释60ml-80ml行瘤体周围粘膜下广泛注射,并于术后应用两药联合灌 注(α-2b干扰素300万U+顺铂50mg)。B组50例仅用顺铂,方法和剂量同A组。结果 101例获得随访5-10年,平均7年。A组和B组存活率分别为73.5％(36/53)和67.4％(31/48),差异元显著性(P>0.05)。但复发率和无瘤存活率分别为26.5％(13/53)和62.3％(313/53)及45.8％和41.7％(20/48),两组差异均有显著性(P<0.05)。结论α-2b干扰素加顺铂粘膜下注射及术后灌注可有效的预防膀胱移行细胞癌术后复发,降低复发率、延迟复发时间,效果优于单用顺铂或干扰素,两药联合有相加和合成作用。
Objective To evaluate the efficacy and safety of combining interferon and cisplatin administration on preventing postoperative superficial bladder cancer recurrence.Methods We restropectively studied 106 patients (trial group 56 cases, control group 50 cases) with bladder transitional cell cancer by injecting cisplatin (control group) or combining interferon - α(IFN - α) and cisplatin (trial group) into the mucosa around tumor during the operation and instilling cisplatin or IFN - α plus cisplatin intravesically after the operation. The size, number, stage and cell differentation of the tumor were similar in control group and trial group. In control group, cisplatin 30mg + NS 50ml was injected into the mucosa around tumor during the operation and cisplatin 50mg + NS50ml was instilled intravesically one week after operation. Once a week for 6, once a month for 8 and three months for 6. In trial group, besides intravesical cisplatin, we plus IFN - α 3 MU from the first intravesical administration.Results 101c ases (trial group 53, control group 40) were followed up for 5 - 10 years (average 7.4 years), 13 cases recurred in trial group and 22 cases in control group, recurrent rate was 26.5% and 45.8%,respectivelly (P> 0.05), the survival rate without tumor was 62.3%(33/53) and 41.7%(20/48),respectively (P<0.05) .Conchusion Combining interferon - α and cisplatin was injected into mucosas around tumor during aperation and intravesical administration after operation may prevent postoperative bladder transitional cell cancer recurrent, reduce tumor recurrent rate, delay tumor recurred time, side effect was unconspicu-ous.
出处
《实用肿瘤学杂志》
CAS
2004年第2期97-100,共4页
Practical Oncology Journal
